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Design, Synthesis, and Characterization
of Urokinase Plasminogen-Activator-Sensitive
Near-Infrared Reporter
The ability to noninvasively map uPA expression repeat-
edly would thus be an important adjunct to current diag-
nostic approaches. Enzyme-linked immunosorbent
assays (ELISAs) [12–14] and immunohistochemistry [15]
are commonly used methods to detect uPA expression
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Harvard Medical School in tissue specimens. Although these techniques are cur-
rently used as the golden standards for analysis ofCharlestown, Massachusetts 02129
2 Proteases and Tissue Remodeling Unit biopsy and surgical specimens, the procedures do not
allow for the direct monitoring of the entire tumors inOral and Pharyngeal Cancer Branch
NIDCR vivo serially over time.
Here, we report on the synthesis, characterization,National Institute of Health
Bethesda, Maryland 20892 and optimization of uPA sensing near-infrared fluores-
cence (NIRF) imaging agents. The approach is based
on substrate-mediated cleavage of NIRF probe from
structurally constrained (and thus quenched) biocom-Summary
patible precursors. Using multiple uPA substrate motifs
(GGSGRSANAKC-NH2) attached to a pegylated graft co-The urokinase-type plasminogen activator (uPA) plays
polymer [16], we show highly sensitive uPA cleavage,a critical role in malignancies, and its overexpression
fluorescence amplification, and the ability to image uPAhas been linked to poor clinical prognosis in breast
inhibition.cancer. The ability to noninvasively and serially map
uPA expression as a biomarker would thus have signif-
icant potential in improving novel cancer therapies. Results and Discussion
Here, we describe the development of a selective uPA
activatable near-infrared (NIR) fluorescent imaging Design of the uPA-Selective Probes
probe. The probe consists of multiple peptide motifs, The designed uPA probes consisting of three compo-
GGSGRSANAKC-NH2, terminally capped with different nents (Figure 1): (1) a nonimmunogenic copolymer of
NIR fluorochromes (Cy5.5 or Cy7) and a pegylated L-lysine (PLL) and methoxy poly(ethylene glycol) (MPEG)
poly-L-lysine graft copolymer. Upon addition of re- as a backbone for substrate attachment and improved
combinant human uPA to the probe, significant fluo- tumoral delivery [16], (2) peptide substrates specifically
rescence amplification was observed, up to 680% with recognized and cleaved by uPA, and (3) the terminal
the optimized preparation. No activation with negative conjugated near-infrared (NIR) fluorochromes as report-
control compounds and uPA inhibitors could be mea- ers [17]. Use of NIRF, rather than visible fluorochromes,
sured. These data indicate that the optimized prepara- enables more efficient photon collection in biological
tion should be useful for imaging uPA in cancer. tissues, due to better tissue penetration, lower scatter-
ing, and lower autofluorescence in the near-infrared
range [18]. Cy5.5 (Ex/Em  675/694 nm) and Cy7 (Ex/Introduction
Em 747/776 nm) were initially selected as model fluor-
ophores given their distinct excitation and emissionThe urokinase plasminogen activator (uPA) and the uPA
wavelengths. The imaging probes were designed so thatreceptor (uPAR) have been shown to facilitate cancer
the fluorochromes were assembled in close proximity,cell invasion into surrounding tissue [1–3] by breaking
resulting in efficient fluorescence quenching (Figure 1).down basement membranes and interstitial matrix [4,
Upon uPA-selective enzymatic cleavage, the fluoro-5]. Urokinase plasminogen activator is an exogenous 52
chromes are released from the delivery backbone, re-kDa serine protease with multiple enzymatic activities
sulting in fluorescence signal.[6] that depend on binding to its cell surface receptor
uPAR [7]. For example, uPA binding to uPAR converts
inactive plasminogen into active plasmin, which in turn Evaluation of the uPA Substrate Specificity
degrades many extracellular proteins including lamin, and Its Cleavage Site
fibronectin, and fibrin [7]. uPA is also known to directly The peptide sequence LGGSGRSANAILE-NH2 has been
activate certain matrix metalloproteinases [8], vascular reported [19] as a highly potent substrate for uPA. It
endothelial growth factor (VEGF), and human growth contains the primary motif SGRSA, which is cleaved 840
factor (HGF) [9]. uPA/uPAR binding is also involved in times (kcat/Km  1200 M1s1) more efficiently than the
gene transcription [7]. native sequence (KKSPGRVVGGSVAH) from plasmino-
High levels of uPA and uPAR have been found in many gen. Here, we modified the parent sequence to
different types of malignancies [10]. In some studies of GGSGRSANAKC-NH2 so that an internal fluorescent
breast [10, 11] and bladder cancer [12], the expression marker, fluorescein isothiocyanate (Fitc), could be
levels of uPA have been correlated with the prognosis. attached to the amino side chain of the lysine residue
during solid-phase peptide synthesis. The introduction
of Fitc was used to easily quantify and follow peptide*Correspondence: tung@helix.mgh.harvard.edu
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Figure 1. Schematic Representation of Protease Selective Probe
The probe is composed with a poly-L-lysine backbone. The peptide substrate was conjugated to a synthetic graft copolymer to promote
efficient tumoral delivery. The close spatial proximity of the multiple substrates leads to fluorescence quenching in the bound state. Upon
enzymatic cleavage, the released peptide fragments result in fluorescence signal amplification.
substrates during subsequent conjugation and purifica- was modified from a previously reported procedure [21]
(Figure 3A). Iodoacetic anhydride was first coupled totion steps. The C-terminal cysteine residue was intro-
duced to provide a thiol-reactive site for peptide conju- the free amino groups of PLL-MPEG. This allows for
the subsequent peptide attachment via a thiol-specificgation to the iodoacetylated PLL-MPEG copolymer. A
scrambled sequence, GGSGASNRAK(Fitc)C-NH2, was reaction and additionally blocks any reactive amino
group on the PLL backbone. Dimethyl formamide (DMF)also synthesized as a control in which the residues be-
tween P1 and P3 were rearranged. Prior to the attach- was used as solvent for peptide conjugation to iodoacet-
ylated PLL-MPEG copolymer. This optimized methodment of the uPA substrates to the graft copolymer, we
confirmed their specificity for uPA by HPLC. Initial stud- also resulted in consistent peptide loading of 17–19 pep-
tides per PLL-MPEG copolymer. Commercially availableies indicated that the uPA substrate peptide, GGS
GRSANAK(Fitc)C-NH2, formed an intermolecular dimer Cy5.5 and Cy7 monofunctional hydroxysuccinamides
were finally attached to the N-terminal glycines of pep-via a disulfide linkage in aqueous buffer (data not
shown). We therefore modified the original sequence tide substrates. Reactions were monitored and charac-
terized by UV absorbance. Both the Cy5.5 and Cy7 uPA-to GGSGRSANAK(Fitc)A-NH2 for enzymatic studies by
replacing the C-terminal cysteine residue with an alanine selective probes showed an absorbance max at 494 nm,
indicating the presence of the peptide marker Fitc (Fig-residue. HPLC chromatography (Figure 2A) indicated
that this substrate sequence was indeed recognized and ure 3B). Additional absorbance peaks for Cy5.5 and Cy7
were observed at 675 nm and 757 nm, respectively.specifically cleaved by uPA. MALDI-TOF MS analyses
(Figure 2B) showed that the digested compound ap- All probes had a high loading efficiency of 88%– 98%,
resulting in an average of 15–19 fluorophores per assem-peared as a single peak at 949.98 Da, which corresponds
to the mass ions [M  H] of SANAK(Fitc)A-NH2. The bled imaging agent (Table 1). The imaging probes were
stable in aqueous buffer at 4C for at least 3 months.site of cleavage was located between the serine and
arginine residue (GGSGR↓SANAK(Fitc)A-NH2), in accor-
dance with what has been previously reported [19]. Activation of the Imaging Probes
Activation of fully assembled imaging probes was testedThere was no enzymatic cleavage of the scrambled con-
trol peptide, GGSGASNRAK(Fitc)A-NH2. Likewise, cleav- by fluorescence spectrophotometry. Incubation of the
Cy5.5 uPA-selective probe with uPA resulted in a 680%age of the substrate peptide was abrogated in the pres-
ence of excess uPA inhibitor, amiloride (Figure 2A) [20]. change in fluorescence over time and reached plateau
within 2 hr (Figure 4A). In contrast, the control probe with
uPA showed essentially no changes in fluorescence. AsSynthesis and Characterization
of the uPA-Selective Probes expected, no fluorescence signal changes were ob-
served without the addition of uPA. To confirm whetherThe synthetic method for the attachment of protease-
specific substrates to the PLL-MPEG graft-copolymer NIRF activation was protease dependent, different con-
Urokinase Plasminogen-Activator-Sensitive Probe
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Figure 2. Specificity of Peptide Substrates
(A) HPLC chromatogram of (a–c) uPA substrate, GGSGRSANAK(Fitc)A, and (d–f) scrambled control, GGSGASNRAK(Fitc)A: (a) substrate alone;
(b) substrate in the presence of urokinase and inhibitor (amiloride); (c) substrate in the presence of urokinase; (d) control alone; (e) control in
the presence of urokinase and inhibitor (amiloride); and (f) control in the presence of urokinase.
(B) The MALDI-TOF mass spectra of urokinase substrate (left) and its digested product (right).
centrations (0, 1, 1.7, 2.0, 2.7, and 3.0 M) of amiloride cence recovery by dividing the fluorescence intensities
of the enzyme-cleaved probes at a particular fluoro-[14], a uPA inhibitor, were applied to block the enzymatic
activity prior to the addition of Cy5.5 uPA-selective chrome concentration with the fluorescence intensities
of the corresponding concentrations of free fluorophoreprobes. The fluorescence emissions of each sample
were recorded at a fixed time point of 2 hr (Figure 4B). (Figure 4D). With 91% of Cy5.5 loading, 98% of the
fluorescence could be recovered. In contrast, with 98%A linear plot (r2  0.989) of fluorescence changes of
Cy5.5 uPA selective probe versus Log [amiloride] indi- of Cy7 loading, only 8% of fluorescence could be recov-
ered. It was also found that Cy7 fluorescence recoverycated that half reduction of NIRF activation was
achieved with 63 M of inhibitor (Figure 4B, inset). (%) decreased inversely with fluorophore loading. How-
ever, the recovery was not complete even with 25% of
Cy7 loading. It has been reported that certain cyanine
Comparison of Cy5.5 and Cy7 fluorophores self-aggregate in solution [22], and this
as Reporter Fluorochromes effect depends on their structure, pH, ionic strength,
In the following experiments, we wished to determine concentration, solvent polarity, electrolyte, and temper-
whether the peptide terminal fluorochrome would have ature [23]. When comparing the chemical structures of
an effect on the magnitude of fluorescence activation. Cy5.5 and Cy7 (Figure 3A), the latter has fewer sulfonate
Surprisingly, the uPA-selective probe that labeled with groups and an extra methine group that contributes to
Cy7 showed a lower increase in fluorescence (moderate hydrophobicity, which may be responsible for aggregate
2.2-fold increase) compared to the Cy5.5 probe (5.8- formation or for intramolecular hydrophobic interaction
fold increase) under identical experimental conditions and result in steric hindrance from the enzyme reactive
(Figure 4C). It is possible to explain the results by differ- site for probe activation.
ent self-quenching properties of the fluorochromes;
however, recent studies have shown that antibodies la-
beled with either Cy5.5 and Cy7 succinimidyl esters have In Vitro Imaging of Probes
Both the Cy5.5 and Cy7 uPA-selective probes were sub-similar quenching efficiencies [22]. In order to further
understand our observations, we calculated the fluores- sequently tested using a NIRF reflectance imaging sys-
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Figure 3. Synthesis and Characterization of uPA-Selective Probes
(A) Synthetic scheme of urokinase-selective probes with (a) Cy5.5 and (b) Cy7 attached as the fluorophores. (I) Iodoacetic anhydride/DIPEA/
DMF/room temperature/3 hr; (II), peptide substrate GGSGRSANAK(Fitc)C/DMF/room temperature/8 hr; (III), Cy5.5 mono NHS ester/NaHCO3/
room temperature/3 hr; and (IV), Cy7 mono NHS ester/NaHCO3/room temperature/3 hr.
(B) UV absorbance spectrum of the Cy5.5- and Cy7-labeled uPA-selective probes (where 1max  Fitc, 2max  Cy5.5, and 3max  Cy7).
tem [24]. To compensate for the differences in activa- system. Images observed in the Cy7 channel showed a
2.9-fold increase in fluorescence activation from the Cy7tion, the exposure time and the number of images
collected for analysis were adjusted accordingly (Figure uPA-selective probe (Figure 5C). Note that there are no
fluorescence emissions from any of the probes when5A). Band-pass filters were employed to adjust the exci-
tation wavelength for Cy 5.5 (615–645 nm) and Cy7 (716– they are not excited from their corresponding channels;
this should ultimately allow the detection of multiple756 nm), respectively, while the corresponding emission
band-pass filters were used to collect the emission sig- enzymes.
nal from 680 to 720 nm for Cy5.5 and 780 to 820 nm
for Cy7. A 6-fold increase in fluorescence signal was
Detection of uPA Activity in Biological Samplesdetected with the Cy5.5 uPA-selective probe within 2
We further investigated the application of uPA-selectivehr after uPA addition (Figure 5B). In contrast, only trace
probe for detection of urokinase in biological samples.amounts of fluorescence were observed in the control
The biological role of uPA has been extensively studiedprobes that containing the scrambled peptide se-
by using uPA-deficient mice (C57BL6/J-uPA/) [25–27].quence. These unwanted signals were attributed to the
Typically, the activity of plasminogen was examined bydye molecules that are conjugated onto the polymer
casein-plasminogen zymography [28]. With the specific
information obtained from the above experiments, we
reasoned that the developed uPA probe could be ap-Table 1. Coupling Efficiency of NIR Fluorochromes to the
plied to determine uPA activity in zymography. To inves-Peptide Synthetic Graft Copolymer
tigate this possibility, urine samples from wild-type
Fluorochromes/ Coupling C57BL6/J mice and uPA knockout C57BL6/J-uPA/
Probe Components Probe Efficiency (%)
mice were collected, and the uPA expression was ana-
Substrate Cy5.5 17 91 lyzed by traditional casein-plasminogen zymography.
Cy7 19 98 As expected, uPA (48 kDa) was only found in the wild-
Control Cy5.5 16 97
type (C57BL6/J) urine but not in the C57BL6/J-uPA/Cy7 15 88
sample (Figures 6A and 6B). The higher band at 70
Coupling efficiency was calculated by dividing the fluorophore con- kDa indicated the expression of tissue plasminogen
centration by the concentration of peptide marker (Fitc).
(tPA). We then cast the SDS-PAGE (7.5% v/v) gel with
Urokinase Plasminogen-Activator-Sensitive Probe
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Figure 4. In Vitro Activation and Inhibition of uPA-Selective Probes
(A) Fluorescence intensity versus time scale (min) on activation of the Cy5.5-labeled probes (200 nM) with urokinase.
(B) Fluorescence changes of Cy5.5 uPA-selective probe (200 nM) versus amiloride concentration (M) at 2 hr after the addition of urokinase.
Inset: fluorescence emission reduces by 50% in the presence of 63 M amiloride.
(C) Comparison of fold increase in fluorescence of Cy5.5 and Cy7 uPA-selective probes on activation with urokinase 2 hr after addition.
(D) Percentage of fluorophore loadings on the uPA-selective probe versus percentage of fluorescence recovery ([Fluorescence Inten-
sityfluorophore-selective probe/Fluorescence Intensityfree fluorophore] 	 100%).
Cy5.5 uPA-selective probe for optical zymography. results indicate that the developed probe is very selec-
tive for uPA. Other proteins and enzymes in the urineUrine samples were prepared as previously described
for regular casein-plasminogen zymography. After elec- sample cannot activate the probe, resulting in no fluo-
rescence signal changes.trophoresis, the separated proteins were renatured by
incubations in 2.5% (v/v) Triton X-100 solution. Under
the Cy5.5 channel, a bright band corresponding to uPA Significance
(48 kDa) in C57BL6/J urine was found coeluted with
human recombinant urokinase in the gel (Figure 6C). No Degradation of the extracellular matrix is a prerequi-
site for invasive growth and metastatic spread of tu-uPA activity was found in the sample collected from
the knockout animal. Notably, the tPA band (70 kDa) mors. Several reports have indicated that uPA is a
possible predictor of disease outcome [10]. The aboveobserved in the regular casein-plasminogen zymogra-
phy was not found in this optical zymographic gel. The studies demonstrate that it is feasible to design and
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its broad role, uPA has also been proposed as a thera-
peutic target [20, 31], and the developed imaging
probes could be used as a direct biomarker to assess
therapeutic efficacy.
Experimental Procedures
Chemicals
All solvents were purchased from Fisher Scientific (Fair Lawn, NJ).
All reagents for peptide synthesis were supplied by Novabiochem
(San Diego, CA). Cy5.5 and Cy7 monofunctional hydroxysuccinam-
ide ester were purchased from Amersham Pharmacia (Piscataway,
NJ). Amiloride, anisole, ethandithiol, fluorescein isothiocyante, thio-
anisole, urokinase, and all other chemical reagents were purchased
from Sigma-Aldrich (St. Louis, MO).
Peptide Synthesis
Peptide synthesis was performed on an automated solid-phase pep-
tide synthesizer (PS3, Rainin, Woburn, MA) employing the traditional
N
-Fmoc methodology on Rink Amide resin (162 mg, 0.1 mmol).
Side-chain protections were Arg(Pbf), Asn(Trt), Cys(Trt), Lys(ivDde),
and Ser(tBu). All amino acids (4 eq.) were attached to the resin by
stepwise elongation using 2(1H-benzotriazole-1-yl)-1,1,3,3-tetra-
methyluronium hexafluorophosphate (HBTU)/N-hydroxybenzotria-
zole (HOBt)/N-methyl morpholine (4/4/8 eq.) as the coupling re-
agents in DMF (10 ml). The peptide N terminus was blocked by
Figure 5. In Vitro Activation of uPA and Control Probes introduction of N-
-t-Boc-glycine. The resulting peptide resin was
washed three times with 2% (v/v) hydrazine monohydrate in DMFImages of Cy5.5 and Cy7 uPA-selective probes and their scrambled
control probes (200 nM) when monitored in (A) white light, (B) 680– (5 ml) for 3 min to selectively remove ivDde (4,4-dimethyl-2,6-dioxo-
cyclohexylidene)3-methylbutyl) side-chain amino protecting group.720 nm (Cy5.5) and (C) 780–820 nm (Cy7) emission channels at 2
hr after the addition of urokinase (1.89 units) in Tris-HCl buffer (50 Fitc (151 mg, 0.4 mmol) dissolved in DMSO (4 ml) was then added
to the resin. The reaction was initiated with the addition of N,N-mM) containing NaCl (50 mM, pH 7.4).
diisopropylethylamine (DIPEA) (1 ml) and was subjected to further
gentle shaking for 8 hr at room temperature. Cleavage of the pep-
tides from the resin and side-chain deprotection employed a mixturesynthesize uPA-specific NIRF imaging probes. Specifi-
of TFA/thioanisole/ethanedithiol/anisole: 90/5/3/2 (5 ml) for 3 hr atcally, we show over 6-fold increases in NIRF signal
room temperature, which was then precipitated into methyl-tert-upon uPA activation with the optimized probes. So far,
butyl ether at 4C. Crude peptides were purified by HPLC (Ranin,
the Cy5.5 containing reporter probe seems superior Worburn, MA) to95% homogeneity. MALDI-TOF mass spectrome-
in terms of activation ratios and should represent an try (Tufts Protein Chemistry Facility, Medford, MA) confirmed the
ideal probe for subsequent NIRF testing. Similarly, as expected mass ions for all synthetic peptides. All peptide concentra-
tions were determined by UV absorbance for its attached Fitc moietyshown for other proteases (e.g., cathepsin B [29], ca-
(  75 	 103 M1cm1 at 494 nm) at pH 9.thepsin D [21], and MMPs [30]), this would involve
testing in tumor models by reflectance [24] or tomo-
Specificity of Peptide Substrategraphic [18] imaging methods. Based on the superior
The peptide substrate GGSGRSANAK(Fitc)A (0.27 g, 0.2 nmol) and
quenching properties of the uPA probe, we have devel- the scrambled control peptide GGSGASNRAK(Fitc)A (0.27 g, 0.2
oped an optical zymography analysis. The method is nmol) were incubated with human urokinase (urine, 100 l, 18.9 unit)
in Tris-HCl buffer (200 l, 50 mM, pH 7.4) containing NaCl (100 mM)specific to uPA activity and is sensitive enough to de-
for 3 min. Amiloride (20 l, 2.5 mM) was used as an inhibitor fortect a small amount of enzyme in biological samples.
urokinase. The enzyme was then removed by centrifugal filtrationOverall, we believe that the developed uPA imaging
(Microcon YM-50), and the filtrate (20 l) was collected and moni-probe should be a valuable adjunct to existing probes,
tored by HPLC (Vydac 218TP54 Reversed Phase C-18 Column, 4.6	
as uPA is critically involved in many cellular and tissue 250 mm). The solution mixture was eluted using a linear gradient
processes, including tumor invasion, metastasis for- starting at 0 min with 18% of 90% (v/v) acetonitrile in 0.1% (v/v)
TFA in deionized water and ending at 30 min with 30% of 90% (v/v)mation, angiogenesis, and tissue remodeling. Given
Figure 6. The Application of uPA-Selective
Probe for Optical Zymography
(A and B) Plasminogen-casein (A) and casein
(B) zymographies confirmed the presence of
uPA in urine from a wild-type (wt) mouse
(C57BL6/J) and indicated that the enzyme is
absent in gene knockout mouse (C57BL6/
J-uPA/).
(C) NIR image of optical zymography. Note
that only the uPA band was found in the wild-
type sample. Other enzymes, including tPA,
in the urine sample could not recognize the
probe and therefore generated no fluores-
cence signal.
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acetonitrile in 0.1% (v/v) TFA in deionized water. The flow rate was loaded onto individual wells of a clear-bottom 96-well plate (Corning,
Corning, NY). Urokinase (20 l, 1.89 unit) was then added to theset at 1 ml/min. Peak elution was monitored at 280 nm, and the
absorbance was recorded from 10 to 20 min. The eluted fractions appropriate wells, and the plate was incubated for 2 hr at room
temperature. It was then exposed to the excitation light source. Thewere separated and collected for further analysis of digested prod-
ucts by MALDI-TOF mass spectrometry. corresponding band-pass filters (Omega Optical, Brattleboro, VT)
were used to filter the fluorescence emission for 680–720 nm (Cy5.5)
and 780–820 nm (Cy7). A 12-bit monochrome CCD camera (Kodak,Synthesis of uPA-Selective Imaging Probes
Rochester, NY) equipped with a 12.5–75 mm zoom lens was usedProtected graft copolymer with a poly-L-lysine backboned (PLL) and
to detect the fluorescent images. The exposure time was 10 s permethyoxy poly(ethylene glycol) (MPEG) side chains was prepared as
image for six images in the Cy5.5 channel and 1 min per image forpreviously described [16]. The uPA probe synthesis was modified
20 images in the Cy7 channel. The images were further analyzedfrom previously developed protocol [21]. Briefly, PLL-MPEG (4 mg,
using computer software (Kodak Digital Science 1D software, Roch-8.8 nmol) was dissolved in DMF (100l) and was added to iodoacetic
ester, NY).anhydride (8 mg, 22.84 mol) in DMF (100 l) with DIPEA (20 l) for
3 hr at 37C. The reaction mixture was then washed with 50% (v/v)
DMF in water and purified by centrifuging through a 50 kDa cutoff Plasminogen-Casein Zymography
filter (Microcon YM-50) to remove any excess reagents, byproducts, Freshly voided urine was collected from a young adult male C57BL6/
and solvents. No free amino groups were found on the iodoacet- J-uPA/ mouse [25, 26] and a matched C57BL6/J mouse (wild-
ylated PLL-MPEG, as monitored by a TNBS assay. The compound type). The samples were immediately snap frozen in liquid nitrogen.
was then redissolved in DMF (200 l) and coupled with the peptide Plasminogen-casein zymography was performed essentially as de-
substrate GGSGRSANAK(Fitc)C (8 mg, 5.74 mol) or the scrambled scribed [28]. Briefly, aliquots of voided urine (2 l) were mixed with
control peptide GGSGASNRAK(Fitc)C (8 mg, 5.74 mol) through a 2% (w/v) sodium dodecyl sulfate (SDS) sample buffer (2 ml) without
thiol-specific reaction for 6 hr at room temperature. The reaction reducing agents and separated on 11% (v/v) SDS-PAGE gels that
mixture was then diluted with water to 500 l and loaded onto were cast with either 22 mg/ml Glu-Plg (Calbiochem, La Jolla, CA)
a size-exclusion column (P-10 bio-gel, Bio-Rad, Hercules, CA) to and 0.64% (w/v) boiled nonfat dry milk powder or with 0.64% (w/v)
remove any excess peptides or byproducts. Coupling efficiency was boiled nonfat dry milk powder alone. The separated proteins were
determined based on the extinction coefficient of the peptide marker renatured by two 30 min incubations in 2.5% (v/v) Triton X-100, and
(Fitc moiety), indicating there was an average of 18–20 peptides the gels were incubated overnight at 37C in glycine (100 mM, pH
coupled to each PLL-MPEG molecule. To introduce near-infrared 8.0). The gels were then stained for 2 hr with 0.1% amido black,
fluorophores to the copolymers, Cy5.5 monofunctional hydroxysuc- destained with 30% (v/v) methanol, 10% (v/v) acetic acid, dried, and
cinamide (0.2 mg, 177 nmol) or Cy7 monofunctional hydroxysucci- scanned.
namide (0.2 mg, 191 nmol) dissolved in NaHCO3 (50 l, 0.1 mM) was
added to the peptide-PLL-MPEG conjugate (0.1 mg) for 3 hr at room Optical Zymography
temperature. The reaction mixtures were then washed and purified The SDS-PAGE gel (7.5%) was freshly prepared by combining deion-
three times with deionized water (200 l) with a 50 kDa cutoff filtra- ized water (4.85 ml), Tris buffer (1.5 M, pH 8.8, 2.5 ml), 10% (w/v)
tion device (Microcon YM-50). The residues were then collected and of SDS (100 l), 30% (w/v) acrylamide containing 1.5% (w/v) bis-
redissolved in water for characterization. acrylamide (2.5 ml), 10% (w/v) ammonium persulfate (50 l) and
TEMED (5 l). The solution mixture was allowed to shake gently for
Characterization of Imaging Probes 2 min. Cy5.5 uPA-selective probe (60 M of dye content, 30 l) was
To determine the number of attached fluorophores to each peptide- then added. The resulting separating gel was poured into a slab gel
PLL-MPEG conjugate, UV absorbance spectra were recorded be- apparatus (Miniprotean II System, Bio-Rad, 5 cm 	 8.5 cm 	 1 mm)
tween 400–850 nm intervals. Both the concentration of peptide to a height of 5.5 cm to allow shrinkage to a final height of 5 cm upon
marker (Fitc) and fluorophores were determined based on their molar polymerization. The acrylamide stacking gel (5%) was composed of
extinction coefficients (494  75 	 103 M1cm1 for Fitc, 675  deionized water (680 l), 30% (w/v) acrylamide containing 1.5%
250 	 103 M1cm1 for Cy5.5, and 747  200 	 103 M1cm1 for (w/v) bis-acrylamide (170 l), Tris buffer (1.5 M, pH 8.8, 130 l), 10%
Cy7, according to the manufacturer data sheets) at pH 9.0. Coupling (w/v) of SDS (10 l), 10% (w/v) ammonium persulfate (10 l), and
efficiency was then calculated by the molar ratio of the attached TEMED (1 l).
fluorophores to the peptide marker. Probes with different coupling Urine samples (2 l) from C57BL6/J-uPA/ or C57BL6/J mice
efficiencies were also synthesized by altering the reaction time for were mixed with 2% (w/v) of SDS (0.5 l). The diluted samples
attachment of activated NIR fluorophores to the peptide-PLL-MPEG were then loaded onto the gels without boiling. Human recombinant
conjugate. urokinase (4 ng) was used as the positive control. The separated
proteins were renatured by incubations in 2.5% (v/v) Triton X-100
Enzymatic Activation in Tris buffer (50 mM, pH 7.4) for 1 hr. The gel was further washed
For ease of comparison, all samples of labeled probes were diluted two times with buffer and imaged by using NIRF reflectance imaging
to the same NIRF concentrations (200 nM based on Cy fluorochrome system as described above.
absorption). Activation of the probes with urokinase (20 l, 1.89
unit) was assayed by fluorescence spectrophotometry (Fluorolog-
Acknowledgments3, Jobin Yvon, Edison, NJ). The samples, in Tris-HCl buffer (1 ml,
50 mM, pH 7.4) containing NaCl (100 mM), were measured in a 4
The authors would like to thank Dr. Vivien Redeye for the techniquemm 	 10 mm 	 1.5 ml disposable semimicro cuvet. The sample
assistance. This research was supported by NIH P50-CA86355,was excited at 674 nm (Cy5.5) and 747 nm (Cy7), and the emission
NO1-CO17016, RO1 CA99385, and DOD DAMD17-02-1-0693.was monitored at 689 nm and 776 nm, respectively. Excitation slit
width was set at 5 nm, while the emission slit width was 10 nm. All
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